A safe and effective treatment for refractory malignant ascites: the use of pigtail catheters.

Akif Do��an, ��mer Ayd��ner
Author Information
  1. Akif Do��an: ��ehit Prof. Dr. ��lhan Varank Training and Research Hospital, Sancaktepe, Turkey.
  2. ��mer Ayd��ner: Dr. L��tfi K��rdar City Hospital, Kartal, Turkey.

Abstract

Purpose: Recurrent malignant ascites is a common and challenging condition in cancer patients, often lacking a standardized treatment protocol. Small-scale studies in the literature have been insufficient to establish a treatment standard. The aim of our study was to investigate the effectiveness and safety of pigtail peritoneal catheter application in the treatment of malignant ascites.
Material and methods: We conducted a retrospective analysis of patients who had pigtail catheters inserted between January 2017 and December 2022. The study focused on the success rate of the procedure, catheter dwell time, complication rates, and the factors influencing these outcomes.
Results: A total of 196 patients, 102 of whom were female, with malignant ascites were included in the study. The median age was 65.5 years. The procedure had a 100% success rate, with no procedure-related deaths or major complications. The overall minor complication rate, including bleeding, minor cellulitis, leakage, and blockage, was 52%. Patients with comorbidities experienced statistically significantly more complications ( < 0.05). The median catheter dwell time was 31 days (range: 3-181 days).
Conclusions: Pigtail peritoneal catheters provide effective and safe minimally invasive fluid drainage for the treatment of malignant ascites. The most critical factors for preventing procedure-related complications and ensuring procedural success include proper indication, correct timing, procedural expertise, and the involvement of well-trained patients and caregivers.

Keywords

References

  1. Case Rep Gastroenterol. 2012 Jan;6(1):166-70 [PMID: 22679405]
  2. Intern Med J. 2020 Jun;50(6):705-711 [PMID: 31566871]
  3. J Cancer Res Ther. 2020 Dec;16(Supplement):S95-S98 [PMID: 33380660]
  4. Eur J Radiol. 2011 Nov;80(2):265-8 [PMID: 20692116]
  5. J Palliat Med. 2022 Jul;25(7):1132-1135 [PMID: 35325569]
  6. Eur J Cancer. 2006 Mar;42(5):589-97 [PMID: 16434188]
  7. Cardiovasc Intervent Radiol. 2018 May;41(5):753-761 [PMID: 29344716]
  8. J Vasc Interv Radiol. 2013 Sep;24(9):1303-8 [PMID: 23876552]
  9. Cardiovasc Intervent Radiol. 2022 Jul;45(7):972-982 [PMID: 35292833]
  10. J Palliat Med. 2014 Aug;17(8):906-12 [PMID: 24885753]
  11. AJR Am J Roentgenol. 2015 Nov;205(5):1126-34 [PMID: 26496562]
  12. Cardiovasc Intervent Radiol. 2022 Nov;45(11):1735-1741 [PMID: 35945349]
  13. Clin Mol Hepatol. 2023 Jan;29(1):16-32 [PMID: 35676862]
  14. AJR Am J Roentgenol. 2001 Sep;177(3):615-8 [PMID: 11517056]
  15. Am Surg. 2011 Aug;77(8):1070-5 [PMID: 21944526]
  16. J Int Med Res. 2021 Feb;49(2):300060520986664 [PMID: 33616416]
  17. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S199-202 [PMID: 14514818]
  18. Gynecol Oncol. 2022 Mar;164(3):639-644 [PMID: 35086684]
  19. Cancers (Basel). 2021 Jun 11;13(12): [PMID: 34208108]
  20. Radiol Oncol. 2016 Feb 07;50(2):197-203 [PMID: 27247552]
  21. J Surg Oncol. 2019 Jul;120(1):67-73 [PMID: 30903617]
  22. Palliat Med. 2022 Oct;36(9):1408-1417 [PMID: 36113139]
  23. Ann Surg Oncol. 1994 Sep;1(5):378-81 [PMID: 7531600]
  24. Int J Clin Oncol. 2013 Feb;18(1):1-9 [PMID: 22460778]

Word Cloud

Created with Highcharts 10.0.0malignantascitestreatmentpatientspigtailcathetersstudycathetersuccessratecomplicationscancerperitonealproceduredwelltimecomplicationfactorsmedianprocedure-relatedminordayseffectivesafeproceduralPurpose:RecurrentcommonchallengingconditionoftenlackingstandardizedprotocolSmall-scalestudiesliteratureinsufficientestablishstandardaiminvestigateeffectivenesssafetyapplicationMaterialmethods:conductedretrospectiveanalysisinsertedJanuary2017December2022focusedratesinfluencingoutcomesResults:total196102femaleincludedage655years100%deathsmajoroverallincludingbleedingcellulitisleakageblockage52%Patientscomorbiditiesexperiencedstatisticallysignificantly<00531range:3-181Conclusions:Pigtailprovideminimallyinvasivefluiddrainagecriticalpreventingensuringincludeproperindicationcorrecttimingexpertiseinvolvementwell-trainedcaregiversrefractoryascites:useend-stage

Similar Articles

Cited By